BioCatalyst

Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE) — catalyst calendar

1 verified catalyst event(s) referencing Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE), each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-07-01
in 9d
ESTIMATED
 READOUT
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination Wit
Phase 2 · Hepatocellular Carcinoma (HCC)
 AZN ASTRAZENECA PLC Durvalumab, Bevacizumab, Transarterial R ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.